Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $32.00 target price on the stock.

Several other research analysts have also recently issued reports on KURA. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Trading Down 3.5 %

Shares of KURA traded down $0.57 during mid-day trading on Wednesday, reaching $15.92. 979,575 shares of the company’s stock traded hands, compared to its average volume of 895,395. Kura Oncology has a 12 month low of $8.80 and a 12 month high of $24.17. The stock has a market cap of $1.24 billion, a P/E ratio of -6.75 and a beta of 0.86. The stock’s 50-day moving average is $18.50 and its two-hundred day moving average is $19.92. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in Kura Oncology by 12.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock worth $874,000 after purchasing an additional 4,659 shares during the period. SG Americas Securities LLC acquired a new stake in Kura Oncology during the 1st quarter worth about $110,000. ProShare Advisors LLC grew its position in Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares during the period. Entropy Technologies LP acquired a new stake in Kura Oncology during the 1st quarter worth about $218,000. Finally, Vanguard Group Inc. grew its position in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.